Wall Street expects a year-over-year increase in earnings on higher revenues when InMode (INMD) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important ...

Despite INMD being down -22% since I recommended to Buy the stock in March, InMode Ltd. remains a highly profitable & innovative leader in the aesthetic industry. Stronger than expected macroeconomic ...

InMode (INMD) has just issued fresh revenue guidance, outlining expectations of US$103.6 million to US$103.8 million for Q4 ...

InMode (INMD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Despite a highly profitable business model and a strong position in the medical aesthetics industry, INMD stock is down -33% over the last 12 months. Macroeconomic pressures, political risks in InMode ...

Inmode ( (INMD)) has released its Q3 earnings. Here is a breakdown of the information Inmode presented to its investors. InMode Ltd. is a global provider of innovative medical technologies, ...

Good day, and welcome to the InMode's third-quarter 2024 earnings results conference call. [Operator instructions] Please note this event is being recorded. I would now like to hand the call to Miri ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to ...

InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a ...

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...